Live price temporarily unavailable.
Lexicon Pharmaceuticals (LXRX) is a Health Care company in the Russell 2000. Latest news and coverage below.
Lexicon Pharmaceuticals revenue & net income history (FY2016–FY2025)
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $79.3M | $91.7M | $63.2M | $322.1M | $24.0M | $298.0K | $139.0K | $1.20M | $31.1M | $49.8M |
| Growth (year over year) | −39.0% | +15.7% | −31.1% | +409.5% | −92.5% | −98.8% | −53.4% | +766.2% | +2481.5% | +60.2% |
| Gross profit | $79.3M | $89.8M | $60.7M | $318.8M | $22.1M | $298.0K | $139.0K | $1.12M | $30.5M | $49.5M |
| Gross margin | 100.0% | 97.9% | 96.1% | 99.0% | 92.0% | 100.0% | 100.0% | 92.9% | 98.0% | 99.4% |
| Operating income | −$127.2M | −$130.6M | −$103.3M | $141.4M | −$47.8M | −$87.1M | −$100.8M | −$171.8M | −$197.1M | −$48.9M |
| Operating margin | −160.5% | −142.5% | −163.4% | 43.9% | −199.2% | −29224.8% | −72489.2% | −14265.0% | −634.2% | −98.2% |
| Net income | −$131.4M | −$123.0M | −$120.5M | $130.1M | −$58.6M | −$87.8M | −$101.9M | −$177.1M | −$200.4M | −$50.3M |
| Net margin | −165.8% | −134.1% | −190.7% | 40.4% | −244.1% | −29449.0% | −73341.0% | −14710.9% | −644.8% | −101.1% |
| EPS (diluted) | −$1.27 | −$1.17 | −$1.14 | $1.16 | −$0.53 | −$0.60 | −$0.62 | −$0.80 | −$0.63 | −$0.14 |
| Balance sheet | ||||||||||
| Cash and equivalents | $46.6M | $61.7M | $80.4M | $36.1M | $126.3M | $64.1M | $46.3M | $22.5M | $66.7M | $34.3M |
| Total assets | $475.6M | $436.5M | $284.1M | $417.7M | $203.8M | $136.9M | $194.3M | $229.4M | $298.4M | $185.0M |
| Total liabilities | $318.2M | $368.3M | $310.5M | $300.6M | $47.4M | $23.3M | $77.2M | $136.3M | $152.5M | $77.4M |
| Long-term debt | $85.2M | $231.6M | $243.9M | $234.2M | $0 | $0 | $48.6M | $99.5M | $100.3M | $49.4M |
| Shareholders' equity | $167.5M | $68.3M | −$26.4M | $117.1M | $156.4M | $113.6M | $117.1M | $93.1M | $145.9M | $107.5M |
| Cash flow | ||||||||||
| Operating cash flow | −$175.6M | −$185.4M | −$148.6M | $113.8M | −$143.0M | −$87.0M | −$88.9M | −$161.9M | −$178.8M | −$67.9M |
| Capital expenditure | $231.0K | $228.0K | $95.0K | $70.0K | $87.0K | $1.22M | $1.33M | $470.0K | $1.03M | $0 |
| Free cash flow | −$175.9M | −$185.6M | −$148.7M | $113.7M | −$143.1M | −$88.2M | −$90.2M | −$162.4M | −$179.8M | −$67.9M |
| Share buybacks | $621.0K | $1.68M | $972.0K | $941.0K | $1.03M | $2.67M | $864.0K | $824.0K | $1.73M | — |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.75M | — | $1.26M | $28.9M | $14.2M | $5.49M | $21.1M | $692.0K |
| Growth (year over year) | +980.2% | — | +11.7% | +1652.6% | +710.4% | — | +1572.1% | −97.6% |
| Gross profit | $1.68M | — | $1.23M | $28.8M | $14.2M | $5.29M | $21.0M | $653.0K |
| Gross margin | 95.9% | — | 97.6% | 99.9% | 99.9% | 96.3% | 99.5% | 94.4% |
| Operating income | −$63.7M | — | −$25.7M | $3.74M | −$12.2M | −$14.8M | −$996.0K | −$26.5M |
| Operating margin | −3639.6% | — | −2034.8% | 12.9% | −85.9% | −269.1% | −4.7% | −3835.3% |
| Net income | −$64.8M | — | −$25.3M | $3.25M | −$12.8M | −$15.5M | −$1.04M | −$31.8M |
| Net margin | −3703.5% | — | −2004.4% | 11.3% | −90.0% | −282.7% | −4.9% | −4591.8% |
| EPS (diluted) | −$0.18 | — | −$0.07 | $0.01 | −$0.04 | −$0.04 | $0.00 | −$0.07 |
| Balance sheet | ||||||||
| Cash and equivalents | $34.6M | $66.7M | $62.9M | $21.4M | $49.7M | $34.3M | $38.1M | $40.9M |
| Total assets | $321.1M | $298.4M | $297.7M | $225.6M | $205.9M | $185.0M | $268.8M | $250.1M |
| Total liabilities | $142.6M | $152.5M | $174.6M | $96.1M | $85.8M | $77.4M | $66.0M | $75.5M |
| Long-term debt | $99.9M | $100.3M | $58.6M | $56.1M | $56.5M | $49.4M | $49.7M | $51.4M |
| Shareholders' equity | $178.5M | $145.9M | $123.0M | $129.4M | $120.2M | $107.5M | $202.9M | $174.5M |
| Cash flow | ||||||||
| Operating cash flow | −$53.6M | — | −$43.8M | $17.0M | −$23.8M | −$17.2M | −$14.7M | −$9.19M |
| Capital expenditure | $307.0K | — | — | — | $0 | $0 | — | — |
| Free cash flow | −$53.9M | — | — | — | −$23.8M | −$17.2M | — | — |
| Share buybacks | $0 | — | — | — | — | — | — | — |
From Lexicon Pharmaceuticals's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
Source: Wikipedia — Lexicon Pharmaceuticals
- Headquarters
- The Woodlands, Texas From SEC filings, Oct 2026
Recent News
No recent news mentioning Lexicon Pharmaceuticals in our feed yet.
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International